Wikidata

(Q40029827)

English

Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3.

scientific article published on February 2008

In more languages

Statements

title
Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3. (English)
1 reference
stated in
Europe PubMed Central
PubMed ID
18163422
retrieved
16 September 2017
author name string
Rebecka Hellsten
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed ID
18163422
retrieved
16 September 2017
Martin Johansson
series ordinal
2
1 reference
stated in
Europe PubMed Central
PubMed ID
18163422
retrieved
16 September 2017
Anna Dahlman
series ordinal
3
1 reference
stated in
Europe PubMed Central
PubMed ID
18163422
retrieved
16 September 2017
Nishtman Dizeyi
series ordinal
4
1 reference
stated in
Europe PubMed Central
PubMed ID
18163422
retrieved
16 September 2017
Olov Sterner
series ordinal
5
1 reference
stated in
Europe PubMed Central
PubMed ID
18163422
retrieved
16 September 2017
Anders Bjartell
series ordinal
6
1 reference
stated in
Europe PubMed Central
PubMed ID
18163422
retrieved
16 September 2017
publication date
1 February 2008
1 reference
stated in
Europe PubMed Central
PubMed ID
18163422
retrieved
16 September 2017
page(s)
269-280
1 reference
stated in
Europe PubMed Central
PubMed ID
18163422
retrieved
16 September 2017

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q40029827&oldid=2127031400"